Chugai Pharmaceutical Co. Ltd. said full-year 2017 profit rose 35.7% from the year-ago period, while revenue grew 8.6%.
The Tokyo-based pharmaceutical company booked net income attributable to shareholders of ¥72.71 billion, up from ¥53.59 billion in the year-ago period.
The company's diluted EPS was ¥132.83, up from ¥97.97 in the previous year.
Revenue for the year ended Dec. 31, 2017, was ¥534.20 billion, up from ¥491.78 billion in the previous year.
For the full year ending Dec. 31, 2018, the Roche Holding AG unit forecasts revenues of ¥541.50 billion, a 1.4% growth year over year. The company also forecasts core EPS of ¥147 for the year, a 6% growth compared to the year-ago period.
As of Jan. 31, US$1 was equivalent to ¥109.27.
